These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17922877)

  • 21. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
    J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.
    Dobson CL; Main S; Newton P; Chodorge M; Cadwallader K; Humphreys R; Albert V; Vaughan TJ; Minter RR; Edwards BM
    MAbs; 2009; 1(6):552-62. PubMed ID: 20068388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
    Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
    Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses.
    Xiao W; Ishdorj G; Sun J; Johnston JB; Gibson SB
    Leuk Lymphoma; 2011 Jul; 52(7):1290-301. PubMed ID: 21699383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
    Gong J; Yang D; Kohanim S; Humphreys R; Broemeling L; Kurzrock R
    Mol Cancer Ther; 2006 Dec; 5(12):2991-3000. PubMed ID: 17148761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
    Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
    Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.
    Menoret E; Gomez-Bougie P; Geffroy-Luseau A; Daniels S; Moreau P; Le Gouill S; Harousseau JL; Bataille R; Amiot M; Pellat-Deceunynck C
    Blood; 2006 Aug; 108(4):1346-52. PubMed ID: 16638930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional analysis of TRAIL receptors using monoclonal antibodies.
    Griffith TS; Rauch CT; Smolak PJ; Waugh JY; Boiani N; Lynch DH; Smith CA; Goodwin RG; Kubin MZ
    J Immunol; 1999 Mar; 162(5):2597-605. PubMed ID: 10072501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.
    Martin BP; Frew AJ; Bots M; Fox S; Long F; Takeda K; Yagita H; Atadja P; Smyth MJ; Johnstone RW
    Int J Cancer; 2011 Jun; 128(11):2735-47. PubMed ID: 20715169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.
    Trarbach T; Moehler M; Heinemann V; Köhne CH; Przyborek M; Schulz C; Sneller V; Gallant G; Kanzler S
    Br J Cancer; 2010 Feb; 102(3):506-12. PubMed ID: 20068564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R
    Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.
    Szliszka E; Mazur B; Zydowicz G; Czuba ZP; Król W
    Folia Histochem Cytobiol; 2009; 47(4):579-85. PubMed ID: 20430723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
    Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
    Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
    Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TRAIL signalling: decisions between life and death.
    Falschlehner C; Emmerich CH; Gerlach B; Walczak H
    Int J Biochem Cell Biol; 2007; 39(7-8):1462-75. PubMed ID: 17403612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin.
    Niyazi M; Marini P; Daniel PT; Humphreys R; Jendrossek V; Belka C
    Oncol Rep; 2009 Jun; 21(6):1455-60. PubMed ID: 19424623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.
    Duiker EW; Dijkers EC; Lambers Heerspink H; de Jong S; van der Zee AG; Jager PL; Kosterink JG; de Vries EG; Lub-de Hooge MN
    Br J Pharmacol; 2012 Apr; 165(7):2203-12. PubMed ID: 22014269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.